PacBio (NASDAQ:PACB) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings
Pacific Biosciences of California (NASDAQ:PACB) reported Q2 CY2026 revenue of $39.01 million, down 1.9% year on year and below analyst expectations. Non-GAAP adjusted EPS was -$0.14, missing consensus. Analysts expect revenue to rise 14.2% over the next 12 months and full-year EPS to improve from -$0.50 to -$0.48. Shares fell 1.1% to $1.28 after results.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term expectation risk after the company missed revenue and adjusted EPS versus consensus, with the stock down 1.1% to $1.28 immediately after results.
Market read
A company-specific earnings miss with explicit Q2 revenue and adjusted EPS figures versus consensus, plus an immediate post-results stock drop.
What to watch
The article highlights improving adjusted operating margin trends over longer windows, which could partially offset the quarter’s top-line weakness if margins continue to improve.
Background
Pacific Biosciences develops HiFi long-read sequencing systems and reported Q2 CY2026 results with a revenue decline and adjusted loss per share.
Ticker impact
PacBio reported Q2 CY2026 revenue of $39.01M, down 1.9% YoY, and adjusted EPS of -$0.14, missing analyst estimates.
Likely continued pressure or elevated volatility around future guidance, given the stock already fell 1.1% to $1.28 immediately after results.
The article provides concrete Q2 figures versus consensus and notes an immediate post-results decline, implying the market reacted negatively to the earnings quality and growth trajectory.
Market effects
Weak prints from a genomics tools provider can reinforce risk-off sentiment toward unprofitable life-science instrumentation names.
Primarily US small/mid-cap biotech and genomics sentiment.
Limited, as the disclosure is company-specific and not a cross-market macro/regulatory event.
Counterpoint
Analysts still expect revenue growth of 14.2% over the next 12 months, suggesting the miss may be a temporary trough rather than a structural demand collapse.
Key entities
- companyPacific Biosciences of California
Subject of the article, reported Q2 CY2026 revenue and adjusted EPS versus analyst estimates.
- groupWall Street analysts
Provided the consensus revenue and EPS expectations that PacBio missed.
